IDEX Corporation FY25 revenue $3.46B (+6%); op income $720M (+3%); NI $483M (-4%); GAAP EPS $6.41. FCF $617M (+2%). Q4 segment performance — HST: organic orders +34% in Q4 2025; volumes increased in data center applications, semiconductor consumables, space + defense; adjusted EBITDA margin +60bp YoY. FMT: organic orders +4%, organic sales +1%; impacted by chemical end-market softness; adjusted EBITDA margin -20bp. FSDP: organic orders flat YoY; organic sales -5% second consecutive quarter; adjusted EBITDA margin +50bp YoY. New CFO Sean Gillen onboarded. Phase three of IDEX purposeful evolution using 8020 playbook (organic + M&A). Completed small acquisition of Microlam. Buyback $248M FY25 (newly resumed; $0 FY24); dividend $213M (+4% YoY). Total debt $1.82B (-8%). FY26 guide: organic growth +1-2%; adjusted EBITDA margin 26-27%; adjusted EPS $8.15-$8.35 (low to mid-single-digit growth YoY); Q1 seasonally soft; Q2 step-up in earnings on volumes + corporate expense normalization. Risks: chemical cycle (FMT), data center / AI capex cycle (HST), semi cycle, M&A pipeline, 8020 execution, industrial cyclical, FX, competitive landscape (Roper, Watts, Pentair, Xylem, Dover).

IDEX 2025-26: HST Orders +34%, FY26 Adj EPS $8.15-$8.35

FY25 revenue $3.46B (+6%); op income $720M (+3%); NI $483M (-4%); GAAP EPS $6.41. FCF $617M (+2%). Q4 segment performance — HST: organic orders +34% in Q4 2025; volumes increased in data center applications, semiconductor consumables, space + defense; adjusted EBITDA margin +60bp YoY. FMT: organic orders +4%, organic sales +1%; impacted by chemical end-market softness; adjusted EBITDA margin -20bp. FSDP: organic orders flat YoY; organic sales -5% second consecutive quarter; adjusted EBITDA margin +50bp YoY. New CFO Sean Gillen onboarded. Phase three of IDEX purposeful evolution using 8020 playbook (organic + M&A). Completed small acquisition of Microlam (integrating well, strong growth momentum). Buyback $248M FY25 (newly resumed; $0 FY24); dividend $213M (+4% YoY). Total debt $1.82B (-8%). FY26 guide: organic growth +1-2%; adjusted EBITDA margin 26-27%; adjusted EPS $8.15-$8.35 (low to mid-single-digit growth YoY); Q1 seasonally soft; Q2 step-up in earnings on higher volumes + corporate expense normalization.

Key takeaways

HST organic orders +34% Q4 — clean order book inflection driven by data center + semi + space/defense. IDEX's Health & Science Technologies (HST) segment delivered organic order growth of +34% in Q4 2025 — a sharp inflection driven by data center applications (cooling + flow control), semiconductor consumables (filtration, sealing), space and defense, and food/pharma markets. Order growth precedes revenue by 1-3 quarters in IDEX's businesses, so the +34% Q4 orders set up a strong revenue trajectory into H1 FY26. HST adj EBITDA margin expanded 60bp YoY despite this volume inflection — operating leverage flowing through.
Phase 3 IDEX purposeful evolution + 8020 playbook — multi-year operational + capital allocation framework. Management is progressing through phase three of IDEX's purposeful evolution using the 8020 playbook (Pareto principle applied to product mix, customer focus, operational discipline). Phase 3 is described as scaling 8020 across operating segments + cross-business unit collaboration + innovation. The 8020 framework drives sustained margin expansion by focusing on highest-value 20% of customers/products that generate 80% of profit. This is the multi-year compounder lever beyond cyclical demand.
HST acceleration in data center + semiconductor — AI infrastructure indirect beneficiary. HST's growth drivers (data center cooling, semiconductor consumables, semi filtration, sealing) are direct AI infrastructure indirect beneficiaries. Hyperscaler AI capex requires liquid cooling solutions (data center), advanced photolithography materials (semi), specialty fluid handling (semi consumables). IDEX's positioning in these niches creates structural growth runway as hyperscaler + foundry capex continues. Multi-year secular tailwind layered onto cyclical recovery.
FMT chemical softness offsetting otherwise strong FY25 — multi-segment cyclical mix dynamics. Fluid & Metering Technologies (FMT) saw chemical end-market softness offsetting other strength: organic orders +4%, sales +1%, adj EBITDA margin -20bp. Chemical demand is at multi-year cycle lows in some sub-segments; recovery would create FMT inflection in FY26+. The chemical softness is the principal drag offsetting HST acceleration in FY25.
FY26 guide: adj EPS $8.15-$8.35 (low-to-mid single digit growth) — conservative on macro + chemical recovery timing. From FY25 adj EPS implied ~$8.00 → FY26 midpoint $8.25 = ~+3% growth. Organic growth 1-2% (vs FY25 +6% reported) reflects management's conservative posture on (a) chemical end-market recovery timing, (b) macro uncertainty, (c) Q1 seasonality. Adj EBITDA margin 26-27% provides flat-to-modest margin expansion. Q2 expected to show pronounced step-up — implies H2-weighted EPS.

Business

IDEX Corporation is a multi-segment specialty industrial conglomerate with multi-product portfolio:

Health & Science Technologies (HST) (~40% of revenue, fastest growing): Specialty pumps + analytical instrumentation + scientific fluidics. Data center cooling, semiconductor consumables, space + defense, food/pharma. Q4 organic orders +34%; adj EBITDA margin +60bp YoY.
Fluid & Metering Technologies (FMT) (~35%): Industrial fluid handling pumps + flow controls + meters. Chemical, water, oil & gas, industrial. Q4 organic orders +4%, sales +1%; chemical softness.
Fire & Safety / Diversified Products (FSDP) (~25%): Fire suppression rescue equipment, dispensing equipment, valves. Q4 orders flat; sales -5% second consecutive quarter; adj EBITDA margin +50bp.
8020 Playbook: Multi-year operational framework focusing on top 20% customers/products generating 80% of profit.

Strategic moves FY25:

HST organic orders +34% Q4
HST acceleration: data center, semiconductor, space/defense, food/pharma
New CFO Sean Gillen onboarded
Phase 3 purposeful evolution + 8020 playbook scaling
Acquired Microlam (small, integrating well, strong growth momentum)
Buyback $248M FY25 (newly resumed vs $0 FY24)
Dividend $213M (+4% YoY)
Total debt $1.82B (-8% YoY)
FY26 guide: revenue +1-2% organic, EPS $8.15-$8.35

FY25 financial performance

Metric (FY)	2022	2023	2024	2025
Revenue ($B)	3.18	3.27	3.27	3.46
Revenue YoY	n/a	+3%	+0%	+6%
Op income ($M)	790	751	697	720
Op margin	24.8%	22.9%	21.3%	20.8%
Net income ($M)	587	596	505	483
Diluted EPS ($)	7.72	7.85	6.64	6.41
FCF ($M)	489	627	603	617
Capex ($M)	-68	-90	-65	-64
Total debt ($B)	1.59	1.45	1.99	1.82
Buyback ($M)	-148	-24	0	-248
Dividends ($M)	-177	-191	-205	-213

The earnings progression: revenue trajectory was flat at $3.27B from FY23-24 reflecting cyclical end-market normalization. FY25 +6% to $3.46B reflects HST acceleration. Op margin compressed from 24.8% (FY22) to 20.8% (FY25) reflecting (a) cyclical mix, (b) M&A integration, (c) inflation pass-through. EPS $6.41 (-3%) reflects modest NI decline + flat share count.

FCF $617M (+2%) — steady cash generation. Total debt $1.82B (-8%). Buyback resumed at $248M.

Capital allocation

Capex: $-64M FY25 (-2% YoY) — capital-light business model.
Dividends: $-213M FY25 (+4% YoY) — progressive dividend.
Buybacks: $-248M FY25 (newly resumed vs $0 FY24).
Total capital return FY25: ~$461M.
Total debt: $1.82B (-8% YoY).
FCF: $617M FY25.

FY26 outlook (per Q4 2025 call, 2026-02-04)

FY26 framework	Detail
Organic growth	+1% to +2%
Adjusted EBITDA margin	26% to 27%
Adjusted EPS	$8.15 to $8.35 (+3-5%)
Q1	Seasonally soft
Q2	Pronounced step-up (volumes + corporate expense normalization)
HST	Continued strength (data center + semi + space/defense)
FMT	Chemical softness recovery monitored
FSDP	Stabilization expected

Management noted continued 8020 playbook execution, HST acceleration, M&A pipeline (small bolt-ons), capital return.

Key risks

Chemical end-market cycle. FMT exposure to chemical industry softness. Multi-year recovery timing matters for FMT inflection.

Data center / AI capex cycle. HST's data center cooling exposure depends on hyperscaler capex. Any AI capex deceleration affects HST trajectory.

Semiconductor cycle. Semiconductor consumables + filtration + sealing demand cyclical. Multi-year semi capex cycle dynamics matter.

M&A pipeline execution. IDEX's growth model is partly M&A-driven; pipeline + valuations + integration matter.

8020 playbook execution risk. Multi-year operational discipline required. Cross-business unit collaboration challenges.

Industrial cycle dynamics. Multi-end-market exposure (industrial, chemical, fire/safety, water, oil/gas) creates cyclical volatility.

Foreign exchange (FX). Multi-region operations exposed to USD/EUR/GBP/JPY translation impacts.

Customer concentration in select sub-niches. HST data center + semi customer concentration in hyperscalers + foundries.

Competitive landscape. Roper Technologies, Watts Water, Pentair, Xylem, Dover, IPG Photonics, others compete in subsets.

Supply chain dynamics. Multi-region manufacturing + specialty components.

Labor + talent retention. Engineering + manufacturing talent multi-year competitive market.

M&A pace + capital deployment. Future bolt-ons or larger acquisitions create capital deployment + integration risk.

Phase 3 purposeful evolution timing. Multi-year strategy execution timing matters.

Sean Gillen CFO transition. New CFO onboarding execution + financial reporting continuity.

Macro / GDP-sensitive industrial demand. Multi-region GDP cycle affects industrial demand.

Bottom line

IDEX FY25 is the multi-segment HST acceleration + 8020 playbook scaling year: revenue $3.46B (+6%); op income $720M (+3%); NI $483M (-4%); EPS $6.41. HST organic orders +34% Q4 driven by data center + semi + space/defense + food/pharma. HST adj EBITDA margin +60bp YoY. FMT organic orders +4%, sales +1%; chemical softness; adj EBITDA margin -20bp. FSDP orders flat; sales -5% 2nd consecutive Q; adj EBITDA margin +50bp. New CFO Sean Gillen. Phase 3 purposeful evolution + 8020 playbook. Microlam acquired. Buyback $248M (resumed); dividend $213M (+4%); total debt $1.82B (-8%).

FY26 guide: organic growth +1-2%; adj EBITDA margin 26-27%; adj EPS $8.15-$8.35 (+3-5%); Q1 soft, Q2 step-up.

The risks are real — chemical end-market cycle (FMT), data center / AI capex cycle (HST), semiconductor cycle, M&A pipeline execution, 8020 playbook execution risk, industrial cycle dynamics, FX, customer concentration in HST sub-niches, competitive landscape (Roper, Watts, Pentair, Xylem, Dover), supply chain dynamics, labor + talent retention, M&A pace, phase 3 purposeful evolution timing, Sean Gillen CFO transition, macro / GDP-sensitive industrial demand.

But the structural thesis (multi-segment specialty industrial conglomerate + HST organic orders +34% Q4 driven by data center + semi + space/defense + 8020 playbook scaling phase 3 + Microlam M&A integrating well + 26-27% adj EBITDA margin guide + $617M FCF capital-light model + selective M&A + multi-year capital return + buyback resumed + new CFO leadership + 8020 multi-year operational framework + cross-segment collaboration) is intact and FY25 confirms.

Quality multi-segment specialty industrial compounder mid-cycle, with HST AI infrastructure indirect beneficiary + 8020 playbook scaling + multi-year M&A pipeline + capital-light cash generation + selective acquisitions + multi-year capital return + new CFO leadership. The HST +34% organic orders Q4 + data center + semi + space/defense acceleration + 8020 phase 3 + Microlam integration + FY26 +1-2% organic + adj EBITDA margin 26-27% + adj EPS $8.15-$8.35 + buyback resumed + multi-year capital return creates one of the cleaner specialty industrial compounding setups for investors seeking exposure to AI infrastructure indirect beneficiaries + 8020 operational discipline + selective M&A + multi-year FCF + capital return. The conservative FY26 framework + HST momentum + chemical recovery optionality + 8020 multi-year framework + M&A pipeline + leadership clarity provides multiple paths to outperformance over a multi-year horizon. Chemical cycle + data center capex + semi cycle + M&A integration + competitive landscape remain ongoing risks, but the multi-segment diversification + HST acceleration + 8020 discipline + capital-light model + capital return support continued compounding through cycles.

Citations

IDEX Corporation FY25 Form 10-K (filed February 2026, SEC EDGAR).
IEX Q4 2025 earnings call, 2026-02-04 — HST: organic orders +34% Q4; volumes increased in data center applications, semiconductor consumables, space + defense; adjusted EBITDA margin +60bp YoY; HST acceleration driven by data center + semi filtration + sealing + space/defense + food/pharma. FMT: organic orders +4%, organic sales +1%; impacted by chemical end-market softness; adjusted EBITDA margin -20bp. FSDP: organic orders flat YoY; organic sales -5% second consecutive quarter; adjusted EBITDA margin +50bp YoY. Sean Gillen introduced as Chief Financial Officer. Phase 3 of IDEX purposeful evolution using 8020 playbook (organic + M&A). Acquired Microlam (small, integrating well, strong growth momentum). FY26 organic growth +1-2%; adjusted EBITDA margin 26-27%; adjusted EPS $8.15-$8.35 (low to mid-single-digit growth YoY); Q1 seasonally soft; Q2 pronounced step-up in earnings on volumes + corporate expense normalization.
IEX Q3 / Q2 / Q1 2025 earnings calls — supporting HST acceleration + FMT chemical softness + FSDP cyclicality + 8020 progression.
Internal financial_statements view (consolidated annual + cash flow + capital structure).

[IEX] IDEX Thesis 2026: Health and Science Technologies Orders Surge, Earnings Guidance Raised